(BRKR) Bruker - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1167941087
BRKR: Scientific, Instruments, Analytical, Solutions, Diagnostics
Bruker Corporation (NASDAQ:BRKR) is a global leader in the development, manufacture, and distribution of scientific instruments and analytical solutions. Headquartered in Billerica, Massachusetts, the company operates through four key segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. Brukers product portfolio includes advanced systems for magnetic resonance spectroscopy, preclinical imaging, biopharma, and applied markets, as well as life science tools, mass spectrometry, and molecular diagnostics. The company also specializes in portable analytical and bioanalytical detection systems, X-ray fluorescence spectrometry, atomic force microscopy, and superconducting materials. Brukers solutions cater to a wide range of applications in life sciences, research, and industrial markets.
Bruker Corporation, founded in 1960, has established itself as a key player in the scientific instrumentation industry. Its products and services support research in translational medicine, drug discovery, and multi-omics, while also providing advanced tools for materials analysis and process control. The companys offerings include non-contact nanometer resolution topography solutions, automated defect detection, and photomask repair equipment. Brukers commitment to innovation and quality has positioned it as a trusted partner for scientists, researchers, and industrial professionals worldwide.
Additional Sources for BRKR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BRKR Stock Overview
| Market Cap in USD | 6,128m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2000-08-04 |
BRKR Stock Ratings
| Growth Rating | -12.6 |
| Fundamental | 1.37 |
| Dividend Rating | 48.8 |
| Rel. Strength | -42.5 |
| Analysts | 3.93/5 |
| Fair Price Momentum | 34.10 USD |
| Fair Price DCF | 19.26 USD |
BRKR Dividends
| Dividend Yield 12m | 0.40% |
| Yield on Cost 5y | 0.52% |
| Annual Growth 5y | 4.56% |
| Payout Consistency | 96.5% |
BRKR Growth Ratios
| Growth Correlation 3m | -88% |
| Growth Correlation 12m | -89.7% |
| Growth Correlation 5y | 12.7% |
| CAGR 5y | 1.03% |
| CAGR/Max DD 5y | 0.02 |
| Sharpe Ratio 12m | -2.02 |
| Alpha | -54.90 |
| Beta | 0.909 |
| Volatility | 52.64% |
| Current Volume | 4926.6k |
| Average Volume 20d | 2129.7k |
As of May 09, 2025, the stock is trading at USD 40.51 with a total of 4,926,588 shares traded.
Over the past week, the price has changed by +2.95%, over one month by +11.41%, over three months by -20.68% and over the past year by -44.84%.
Neither. Based on ValueRay Fundamental Analyses, Bruker is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 1.37 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BRKR as of May 2025 is 34.10. This means that BRKR is currently overvalued and has a potential downside of -15.82%.
Bruker has received a consensus analysts rating of 3.93. Therefor, it is recommend to buy BRKR.
- Strong Buy: 6
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BRKR Bruker will be worth about 37.5 in May 2026. The stock is currently trading at 40.51. This means that the stock has a potential downside of -7.43%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 60.1 | 48.4% |
| Analysts Target Price | 60.1 | 48.4% |
| ValueRay Target Price | 37.5 | -7.4% |